Kymera Therapeutics (NASDAQ:KYMR) Shares Gap Down – Time to Sell?

Kymera Therapeutics, Inc. (NASDAQ:KYMR)’s share price gapped down prior to trading on Wednesday . The stock had previously closed at $45.98, but opened at $44.75. Kymera Therapeutics shares last traded at $44.75, with a volume of 4,250 shares changing hands.

Analysts Set New Price Targets

KYMR has been the topic of a number of recent analyst reports. Guggenheim upped their price target on shares of Kymera Therapeutics from $45.00 to $52.00 and gave the stock a “buy” rating in a research note on Friday, November 1st. Oppenheimer upped their price target on shares of Kymera Therapeutics from $52.00 to $56.00 and gave the stock an “outperform” rating in a research note on Friday, September 27th. Leerink Partners reaffirmed an “outperform” rating and set a $60.00 price target on shares of Kymera Therapeutics in a research note on Monday, September 9th. Morgan Stanley upped their price target on shares of Kymera Therapeutics from $45.00 to $49.00 and gave the stock an “equal weight” rating in a research note on Wednesday, November 6th. Finally, Truist Financial reaffirmed a “buy” rating and set a $53.00 price target (down from $54.00) on shares of Kymera Therapeutics in a research note on Friday, November 1st. Four analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Kymera Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $52.13.

Kymera Therapeutics Trading Up 1.8 %

The company’s fifty day moving average price is $46.91 and its two-hundred day moving average price is $42.04.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings data on Thursday, October 31st. The company reported ($0.82) earnings per share for the quarter, topping the consensus estimate of ($0.83) by $0.01. The business had revenue of $3.74 million for the quarter, compared to analyst estimates of $10.34 million. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The company’s revenue was down 20.9% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.90) EPS. As a group, research analysts anticipate that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current year.

Insider Transactions at Kymera Therapeutics

In related news, Director Pamela Esposito sold 13,500 shares of the stock in a transaction that occurred on Tuesday, September 17th. The shares were sold at an average price of $48.28, for a total transaction of $651,780.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 15.82% of the company’s stock.

Institutional Trading of Kymera Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of KYMR. FMR LLC grew its position in Kymera Therapeutics by 5.8% in the third quarter. FMR LLC now owns 5,109,141 shares of the company’s stock valued at $241,816,000 after acquiring an additional 282,301 shares in the last quarter. Vanguard Group Inc. grew its position in Kymera Therapeutics by 19.2% in the first quarter. Vanguard Group Inc. now owns 4,767,050 shares of the company’s stock valued at $191,635,000 after acquiring an additional 769,486 shares in the last quarter. Wellington Management Group LLP grew its position in Kymera Therapeutics by 7.2% in the third quarter. Wellington Management Group LLP now owns 4,618,359 shares of the company’s stock valued at $218,587,000 after acquiring an additional 308,954 shares in the last quarter. Artal Group S.A. grew its position in shares of Kymera Therapeutics by 19.6% during the first quarter. Artal Group S.A. now owns 3,027,135 shares of the company’s stock worth $121,691,000 after buying an additional 496,400 shares in the last quarter. Finally, Jennison Associates LLC grew its position in shares of Kymera Therapeutics by 85.8% during the third quarter. Jennison Associates LLC now owns 797,681 shares of the company’s stock worth $37,754,000 after buying an additional 368,394 shares in the last quarter.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.